Impact of COVID-19 Vaccination Program on Seroprevalence in Blood Donors in England, 2021

12 Pages Posted: 30 Mar 2021

See all articles by Heather Whitaker

Heather Whitaker

Government of the United Kingdom - Public Health England Colindale

Suzanne Elgohari

Government of the United Kingdom - Public Health England

Cathy Rowe

Public Health England

Ashley Otter

Public Health England

Tim Brooks

Public Health England

Ezra Linley

Public Health England, Manchester Royal Infirmary

Iain Hayden

Government of the United Kingdom - Immunisation and Countermeasures Division

Sonia Ribeiro

Government of the United Kingdom - Immunisation and Countermeasures Division

Jacqueline Hewson

Public Health England

Anissa Lakhani

Government of the United Kingdom - Immunisation and Countermeasures Division

Eleanor Clarke

Government of the United Kingdom - Immunisation and Countermeasures Division

Camille Tsang

Government of the United Kingdom - Immunisation and Countermeasures Division

Colin Campbell

Government of the United Kingdom - Public Health England

Mary E. Ramsay

Public Health England - Immunisation, Hepatitis, and Blood Safety Department

Kevin Brown

Public Health England

Gayatri Amirthalingam

Public Health England - Immunisation and Countermeasures Division

Date Written: March 16, 2021

Abstract

The COVID-19 vaccination programme commenced in the UK on 8th December 2020 primarily based on age; by 24 February 2021 approximately 93% of the English population aged 70-79 years had received at least 1 dose of either the Pfizer BioNTech or AstraZeneca vaccines. Using a nucleoprotein assay that detects antibodies following natural infection only and a spike assay that detects both infection and vaccine-induced responses, we aim to describe the impact of vaccination on SARS-CoV-2 antibody prevalence in English blood donors.

Note: Funding Statement: Funding was provided through Public Health England.

Declaration of Interests: EL reports the Public Health England Vaccine Evaluation Unit performs contract research on behalf of GSK, Sanofi and Pfizer which is outside the submitted work. HW, SE, IH, SR, KB, GA, EC, AL, CT, CC, IH, SR, JH, CR, AO, TB, MR report no conflicts of interest.

Ethics Approval Statement: PHE has legal permission, provided by Regulation 3 of The Health Service (Control of Patient Information) Regulations 2002, to process patient information for national surveillance of communicable diseases. Specific ethical approval was not required for this surveillance work.

Keywords: COVID-19, blood donor, serological survey

JEL Classification: I18

Suggested Citation

Whitaker, Heather and Elgohari, Suzanne and Rowe, Cathy and Otter, Ashley and Brooks, Tim and Linley, Ezra and Hayden, Iain and Ribeiro, Sonia and Hewson, Jacqueline and Lakhani, Anissa and Clarke, Eleanor and Tsang, Camille and Campbell, Colin and Ramsay, Mary E. and Brown, Kevin and Amirthalingam, Gayatri, Impact of COVID-19 Vaccination Program on Seroprevalence in Blood Donors in England, 2021 (March 16, 2021). Available at SSRN: https://ssrn.com/abstract=3803380 or http://dx.doi.org/10.2139/ssrn.3803380

Heather Whitaker (Contact Author)

Government of the United Kingdom - Public Health England Colindale ( email )

61 Colindale Avenue
London, NW9 5EQ
United Kingdom

Suzanne Elgohari

Government of the United Kingdom - Public Health England

Wellington House
133-155 Waterloo Road
London, SE1 8UG
United Kingdom

Cathy Rowe

Public Health England

Wellington House,
133-155 Waterloo Rd,
London, SE1 8UG
02083277520 (Phone)
NW9 5EQ (Fax)

Ashley Otter

Public Health England ( email )

Wellington House,
133-155 Waterloo Rd,
London, SE1 8UG

Tim Brooks

Public Health England ( email )

Wellington House,
133-155 Waterloo Rd,
London, SE1 8UG

Ezra Linley

Public Health England, Manchester Royal Infirmary ( email )

Iain Hayden

Government of the United Kingdom - Immunisation and Countermeasures Division

61 Colindale Avenue
London, NW9 5EQ
United Kingdom

Sonia Ribeiro

Government of the United Kingdom - Immunisation and Countermeasures Division

61 Colindale Avenue
London, NW9 5EQ
United Kingdom

Jacqueline Hewson

Public Health England

Wellington House,
133-155 Waterloo Rd,
London, SE1 8UG

Anissa Lakhani

Government of the United Kingdom - Immunisation and Countermeasures Division

61 Colindale Avenue
London, NW9 5EQ
United Kingdom

Eleanor Clarke

Government of the United Kingdom - Immunisation and Countermeasures Division

61 Colindale Avenue
London, NW9 5EQ
United Kingdom

Camille Tsang

Government of the United Kingdom - Immunisation and Countermeasures Division

61 Colindale Avenue
London, NW9 5EQ
United Kingdom

Colin Campbell

Government of the United Kingdom - Public Health England

Wellington House
133-155 Waterloo Road
London, SE1 8UG
United Kingdom

Mary E. Ramsay

Public Health England - Immunisation, Hepatitis, and Blood Safety Department ( email )

United Kingdom

Kevin Brown

Public Health England ( email )

Wellington House,
133-155 Waterloo Rd,
London, SE1 8UG

Gayatri Amirthalingam

Public Health England - Immunisation and Countermeasures Division ( email )

Wellington House
133-155 Waterloo Road
London, SE1 8UG
United Kingdom

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
101
Abstract Views
559
rank
314,600
PlumX Metrics